The Journal of Bone and Joint Surgery (American). 2008;90:43-47.
doi:10.2106/JBJS.G.01090
© 2008 The Journal of Bone and Joint Surgery, Inc.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldhahn, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldhahn, J.
Related Collections
Right arrow Basic Science
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Facebook   Add to Technorati   Add to Twitter  
What's this?

Critical Issues in Translational and Clinical Research for the Study of New Technologies to Enhance Bone Repair

Jörg Goldhahn, MD, Bruce Mitlak, MD, Per Aspenberg, MD, PhD, John A. Kanis, MD, René Rizzoli, MD, Jean-Yves Reginster, MD, PhD the GREES (Group for the Respect of Ethics and Excellence in Science) Working Group on Bone Fracture-Healing

Corresponding author:
Jörg Goldhahn, MD
Department of Research, Schulthess Klinik, Lengghalde 2, Zurich 8008, Switzerland.
E-mail address: joerg.goldhahn{at}kws.ch

Disclosure: The authors did not receive any outside funding or grants in support of their research for or preparation of this work. One or more of the authors, or a member of his or her immediate family, received, in any one year, payments or other benefits of less than $10,000 or a commitment or agreement to provide such benefits from a commercial entity (Eli Lilly and Company). No commercial entity paid or directed, or agreed to pay or direct, any benefits to any research fund, foundation, division, center, clinical practice, or other charitable or nonprofit organization with which the authors,or a member of their immediate families, are affiliated or associated.

NOTE: The GREES (Group for the Respect of Ethics and Excellence in Science) working group on bone fracture-healing consists of the following individuals: Eric Abadie, Per Aspenberg, Peter Augat, Maria-Luisa Brandi, Nansa Burlet, Arkadi Chines, Pierre Delmas, Will Dere, Isabelle Dupin-Roger, Dominique Ethgen, Jörg Goldhahn, John A. Kanis, Joel Krasnow, Gottfried Kreutz, Andrea Laslop, Frits Lekkerkerker, David Marsh, Bruce Mitlak, Sif Ormarsdottir, Jean-Yves Reginster, René Rizzoli, Art Santora, Gerhard Schmidmaier, and Michael Wagener.

Osteoporosis increases fracture risk, especially in metaphyseal bone. Fractures seriously impair function and quality of life and incur large direct and indirect costs. Although the prevention of fractures is certainly the option, a fast and uneventful healing process is optimal when fractures do occur. Many new therapeutic strategies have been developed to accelerate fracture-healing or to diminish the complication rate during the course of fracture-healing. However, widely accepted guidelines are needed to demonstrate the positive or negative interactions of bioactive substances, drugs, and other agents that are being used to promote fracture-healing. For each study design, the primary study goal should be indicated. Outcome variables should include both objective and subjective parameters. The guidelines should be harmonized between European and American regulatory authorities to ensure comparability of results of studies and to foster global harmonization of regulatory requirements.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Facebook Facebook   Add to Technorati Technorati   Add to Twitter Twitter    What's this?